ABSTRACT
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and commonly associated with activating mutations in the Notch1 pathway. (-)-Epigallocatechin-3-gallate (EGCG) is the most abundant and active catechin and has been shown to regulate Notch signaling. Taking into account the highly oxidizable and unstable of EGCG, we proposed that EGCG oxides may have greater potential to regulate Notch signaling than EGCG. In this study, we isolated and identified EGCG oxides (compound 2-4), using a chemical oxidation strategy, and evaluated for cytotoxicity against T-cell acute lymphoblastic leukemia cell line (HPB-ALL) by using the MTS assay. We found compound 3 significantly induced cell proliferation inhibition (38.3858 ± 1.67106 µM), cell apoptosis and cell cycle arrest in a dose-dependent manner. Remarkably, compound 3 inhibited expression of Notch1 compared with EGCG in HPB-ALL cells. Meanwhile, we found that compound 3 significantly inhibited c-Myc and Hes1, which are downstream target genes of Notch1. The findings demonstrate for the first time that an oxidation product of EGCG (compound 3) inhibits T-cell acute lymphoblastic leukemia cell line (HPB-ALL) and is a promising agent for cancer therapy deserving further research.
ABSTRACT
BACKGROUND: This analysis was conducted to evaluate the efficacy and safety of Trans-arterial Chemo- Embolization (TACE) in treating Elderly patients with Hepatocellular Carcinoma (EHPC). METHODS: Clinical studies evaluating the efficacy and safety of TACE on response and safety for patients with EHPC were identified by using a predefined search strategy. Pooled response rate of treatment were calculated. RESULTS: In TACE based regimen, clinical studies which including patients with EHPC were considered eligible for the evaluation of response. And, in these TACE based treatments, pooled analysis suggested that, in all 288 patients whose response could be assessed, the pooled reponse rate was 29.5%(85/288) in TACE based treatment. The most commonly encountered TACE-related morbidity was liver function impairment. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred in EHPC patients with TACE based treatments. CONCLUSION: This evidence based analysis suggests that TACE based treatments are associated with mild response rate and accepted toxicities for treating patients with EHPC.
Subject(s)
Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic , Liver Neoplasms/therapy , Aged , Female , Follow-Up Studies , Humans , Male , Neoplasm Staging , Prognosis , Remission InductionABSTRACT
BACKGROUND/AIMS: To explore the relationships among differentiation degree, contrast-enhanced ultrasound and the expression of EphB4/EphrinB2 in primary hepatocarcinoma. METHODOLOGY: Forty one patients that were diagnosed with hepatocarcinoma by contrast-enhanced ultrasound before operation and then confirmed to have primary hepatocarcinoma by postoperative pathology were enrolled in our study. The expression of EphB4/EphrinB2 in tumor specimens were detected by immunohistochemical assay and compared with the result of contrast-enhanced ultrasound. RESULTS: Differentiation degree was related to EphrinB2 expression and contrast-enhanced ultrasound in primary hepatocarcinoma. EphrinB2 expression was significantly higher in poorly differentiated hepatocarcinoma (88.9%, 16/18) then in moderately and well differentiated hepatocarcinoma (34.8%, 8/23) (?2=12.17, p<0.001). The 'fast-in' in arterial phase displayed by contrast-enhanced ultrasound was also significantly higher in poorly differentiated hepatocarcinoma (100%) than in moderately and well differentiated hepatocarcinoma (60.9%, 14/23) (?2=9.02, p=0.003). CONCLUSIONS: EphrinB2 is an important indicator of poorly differentiated hepatocarcinoma. There is a good correlation of EphrinB2 expression with vascular perfusion pattern and morphology in arterial phase displayed by contrast-enhanced ultrasound, so contrast-enhanced ultrasound has a certain value in evaluating differentiation degree of primary hepatocarcinoma before operation.
Subject(s)
Carcinoma, Hepatocellular/pathology , Ephrin-B2/analysis , Liver Neoplasms/pathology , Receptor, EphB4/analysis , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/chemistry , Carcinoma, Hepatocellular/diagnostic imaging , Cell Differentiation , Contrast Media , Female , Humans , Image Enhancement , Immunohistochemistry , Liver Neoplasms/blood supply , Liver Neoplasms/chemistry , Liver Neoplasms/diagnostic imaging , Male , Middle Aged , UltrasonographyABSTRACT
Our previous study demonstrated that apelin level increased significantly after the treatment of intracoronary implantation of bone marrow mononuclear cells (BMMCs), followed by the improvement of cardiac function in patients with severe ischemic heart failure. The present studies both in vivo and in vitro explored whether mesenchymal stem cells derived from bone marrow (BMSCs) activate the apelin-APJ pathway when differentiating into cardiomyogenic cells. Isolated BMSCs from rat femurs and tibias were cultured and expanded for three passages, labeled with DAPI, and treated with 5-azacytidine (5-AZ). BMSCs labeled with ad-EGFP were injected intramyocardially into the peri-infarct area of rat models with acute myocardial infarction. Immunofluorescence staining exposed that CMGs expressed apelin together with myogenic-specific proteins such as α-actin, troponin T, GATA-4, and connexin-43 at 7 days after 5-AZ treatment or EGFP-BMSC injection. RT-PCR revealed that mRNA in CMGs started to express apelin and APJ from day 7 and progressively increased until day 28. Cardiac function, as measured by echocardiography in vivo, was significantly improved in parallel with the extent of apelin expression after BMSC transplantation. Our finding indicated that the expression of the apelin-APJ pathway during differentiation of BMSCs into CMGs may be an important mechanism in regulation of myocardial regeneration and functional recovery after BMSC transplantation.
Subject(s)
Carrier Proteins/metabolism , Mesenchymal Stem Cells/cytology , Myocytes, Cardiac/metabolism , Receptors, G-Protein-Coupled/metabolism , Actins/metabolism , Animals , Antimetabolites, Antineoplastic/pharmacology , Apelin , Apelin Receptors , Azacitidine/pharmacology , Cell Differentiation , Cells, Cultured , Connexin 43/metabolism , GATA4 Transcription Factor/metabolism , Intercellular Signaling Peptides and Proteins , Microscopy, Fluorescence , Myocardial Infarction/metabolism , Myocytes, Cardiac/cytology , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/genetics , Signal Transduction , Troponin T/metabolismABSTRACT
AIM: The type I insulin-like growth factor receptor (IGF-IR) is overexpressed in many tumors including human hepatocellular carcinoma (HCC). It is a critical signaling molecule for tumor cell proliferation and survival. In the present study, IGF-IR expression was down-regulated by phosphorothioate antisense oligonucleotides (AS[S]ODN) to evaluate their specific effects on growth of hepatoma cells in vitro and in vivo. METHODS: HepG2 cells were transfected with different doses of AS[S]ODN, sense [S]ODN, mismatch [S]ODN, or Lipofectin for 72 h, and cell proliferation was analyzed by MTS assay. In vivo, an orthotopic transplant model of HCC was established in nude mice, which were then injected with AS[S]ODN, sense [S]ODN, 5-fluorouracil or saline. At the endpoint of treatment, the tumors were excised and evaluated. RESULTS: Compared to sense and mismatched oligonucleotides, AS[S]ODN targeting to IGF-IR mRNA significantly inhibited hepatoma cell lines HepG2 proliferation and IGF-IR expression at both mRNA and protein levels. The in vivo results showed that systemic treatment also resulted in significant inhibition in tumor growth. Tumor growth in mice treated with AS[S]ODN (50 and 75 mg/kg per day) was significantly inhibited (71.81% and 61.74%, respectively) compared to the saline-treated group (P < 0.01) in a dose-dependent manner. The antitumor effect of IGF-IR AS[S]ODN was associated with down-regulation of IGF-IR in tumor xenografts. Furthermore, IGF-IR AS[S]ODN prevented liver recurrence tumor growth and metastasis in the lung, showing a dose-dependent response. The level of serum alpha-fetoprotein in AS[S]ODN-treated groups was also decreased in a dose-dependent manner, and a good correlation was observed between tumor volume and serum alpha-fetoprotein concentration. CONCLUSIONS: These data suggest that IGF-IR AS[S]ODN can effectively and specifically inhibit HCC growth in vitro and in vivo. Blockage of IGF-IR expression could be a promising therapeutic approach for the management of patients with HCC.